Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3ζ from human pluripotent stem cells

9 Oct 2024

Abstract excerpt

Background Macrophages engineered with chimeric antigen receptors (CAR) are suitable for immunotherapy based on their immunomodulatory activity and ability to infiltrate solid tumours. However, the production and application of genetically edited, highly effective, and mass-produced CAR-modified macrophages (CAR-Ms) are challenging. Methods Here, we used homology-independent targeted insertion (HITI) for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune cells in cancer
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39383607
DOI: 10.1016/j.ebiom.2024.105390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3ζ from human pluripotent stem cellsPMID 39383607Read ↗

Large-scale generation of IL-12 secreting macrophages from human pluripotent stem cells for cancer therapySemantic proximity Read ↗

Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapiesSemantic proximity Read ↗

Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity.Semantic proximity Read ↗

Enhanced anti-tumor effects through continuous administration of engineered CAR-macrophages derived from pluripotent stem cell-derived myeloid cell linesSemantic proximity Read ↗

Chimeric antigen receptors that trigger phagocytosisSemantic proximity Read ↗

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentationSemantic proximity Read ↗

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Semantic proximity Read ↗

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responsesSemantic proximity Read ↗

Phenotypic comparison and the potential antitumor function of immortalized bone marrow-derived macrophages (iBMDMs)Semantic proximity Read ↗

Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cellsSemantic proximity Read ↗

Induced Pluripotent Stem Cell-Based Cancer Immunotherapy: Strategies and PerspectivesSemantic proximity Read ↗

Phenotypic comparison and the potential antitumor function of immortalized bone marrow-derived macrophages (iBMDMs).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.